Trials / Completed
CompletedNCT01128257
A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis
Controllability and Real Life Efficacy of Bonviva 3 mg iv Quarterly vs. Oral Alendronate Generics
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 6,054 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- Female
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will assess the compliance and persistence of patients, real life efficacy and safety of intravenously quarterly administered 3 mg ibandronate \[Bonviva/Boniva\] in comparison to oral alendronate generics in female patients with post-menopausal osteoporosis. The anticipated time of assessment is 12 months. The target sample size is 5000-7000 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | alendronate | As prescribed by physician |
| DRUG | ibandronate [Bonviva/Boniva] | As prescribed by physician |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2010-05-21
- Last updated
- 2016-11-02
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01128257. Inclusion in this directory is not an endorsement.